Alaunos Therapeutics (TCRT) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Alaunos Therapeutics (TCRT) over the last 13 years, with Q1 2025 value amounting to 54600.0%.
- Alaunos Therapeutics' EBIT Margin rose 1196000000.0% to 54600.0% in Q1 2025 from the same period last year, while for Sep 2025 it was 67883.33%, marking a year-over-year increase of 1322333300.0%. This contributed to the annual value of 48120.0% for FY2024, which is 6372200000.0% up from last year.
- Per Alaunos Therapeutics' latest filing, its EBIT Margin stood at 54600.0% for Q1 2025, which was up 1196000000.0% from 18875.0% recorded in Q4 2024.
- Alaunos Therapeutics' 5-year EBIT Margin high stood at 283.89% for Q3 2022, and its period low was 794900.0% during Q4 2023.
- Over the past 5 years, Alaunos Therapeutics' median EBIT Margin value was 66031.82% (recorded in 2025), while the average stood at 190717.45%.
- In the last 5 years, Alaunos Therapeutics' EBIT Margin crashed by 2000000000bps in 2023 and then surged by 2000000000bps in 2024.
- Over the past 5 years, Alaunos Therapeutics' EBIT Margin (Quarter) stood at 552550.0% in 2021, then skyrocketed by 86bps to 77463.64% in 2022, then crashed by -926bps to 794900.0% in 2023, then soared by 98bps to 18875.0% in 2024, then tumbled by -189bps to 54600.0% in 2025.
- Its last three reported values are 54600.0% in Q1 2025, 18875.0% for Q4 2024, and 29150.0% during Q2 2024.